Single Arm Phase II Study of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder as Second Line Treatment.
Phase of Trial: Phase II
Latest Information Update: 24 May 2018
At a glance
- Drugs Lapatinib (Primary) ; Docetaxel
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- 08 Apr 2017 Planned End Date changed from 1 Jul 2016 to 15 Dec 2017.
- 05 Feb 2014 Status changed from active, no longer recruiting to discontinued.
- 26 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.